In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taisho Pharmaceutical Co. Ltd.

www.taisho.co.jp

Latest From Taisho Pharmaceutical Co. Ltd.

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Consumer Health Results Roundup: Genomma, Ipsen And Taisho

Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.
Sales & Earnings OTC Drugs

Taisho Wraps BMS Consumer Health Acquisition; iAnthus Nabs CBD For Life; Health & Wellness M&A In Brief

Bristol-Myers Squibb is free to focus on drug development for patients facing serious diseases, with the divestment of its UPSA consumer health business to Taisho now complete. Separately, Harvest One Cannabis and iAnthus Capital Holdings build their capabilities to meet soaring demand for CBD and other cannabis-derived health, wellness and beauty products.

Health Wellness

Japan's Taisho Suffers Declines At Home And Abroad As It Ends Disappointing Year

With sales falling across the board in 2018, Taisho is counting on acquisitions overseas and new organic growth initiatives at home to turn the tide.
Sales & Earnings OTC Drugs
See All

Company Information

UsernamePublicRestriction

Register